Notices. Notice
730 words·~3 min read·
/register/2022/10/07/2022-21840·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2011-N-0902] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration
(FDA)is announcing that a proposed collection of information has been submitted to the Office of Management and Budget
(OMB)for review and clearance under the Paperwork Reduction Act of 1995. DATES: Submit written comments (including recommendations) on the collection of information by November 7, 2022. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0393. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-5733, *PRAStaff@fda.hhs.gov.* SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Medication Guide Requirements for Prescription Drug Product Labeling OMB Control Number 0910-0393—Extension This information collection supports FDA regulations pertaining to the distribution of patient labeling, called Medication Guides, for human prescription drug and biological products used primarily on an outpatient basis, and required for products that pose a serious and significant public health concern. Applicable regulations are codified at part 208 (21 CFR part 208): Medication Guides for Prescription Drug Products, and set forth general content and format requirements, as well as provide for exemptions and deferrals. Medication Guides provide patients with important written information about drug products, including the drug's approved uses, contraindications, adverse drug reactions, and cautions for specific populations, and are required in accordance with Agency regulations. To assist consumers and industry with understanding applicable regulatory requirements in part 208 pertaining to developing, distributing, and submitting certain Medication Guides, we have developed the guidance document entitled “Medication Guides—Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)” (available at *https://www.fda.gov/media/79776/download* ). The guidance document includes:
(1)a discussion of the applicable regulations;
(2)FDA enforcement policy with regard to Medication Guides associated with products dispensed to healthcare professionals, or patient caregivers, instead of being dispensed directly to the patient for self-administration; and
(3)Medication Guides required as part of a risk evaluation and mitigation strategy. In the **Federal Register** of March 22, 2022 (87 FR 16199), we published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. We estimate the burden of this collection of information as follows: Table 1—Estimated Annual Reporting Burden 1 Activity; 21 CFR section Number of respondents Number of responses per respondent Total annual responses Average burden per response Total hours Content and format of a Medication Guide; § 208.20 41 1 41 320 13,120 Exemptions and deferrals; § 208.26(a) 1 1 1 4 4 Total 42 13,124 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Upon evaluation of the information collection, we have removed burden we attributed to reporting associated with supplements and other changes to approved abbreviated new drug applications, new drug applications, and biologics license applications (21 CFR 314.70(b)(3)(ii) and 601.12(f)). We now account for burden associated with these regulatory provisions in OMB control numbers 0910-0001 and 0910-0338 and have decreased the burden associated with this collection accordingly. Table 2—Estimated Annual Third-Party Disclosure Burden 1 Activity; 21 CFR section Number of respondents Number of disclosures per respondent Total annual disclosures Average burden per disclosure 2 Total hours Distribute Medication Guides to authorized dispensers; § 208.24(c) 191 9,000 1,719,000 1.25 2,148,750 Distribute and Dispense Medication Guides to Patients; § 208.24(e) 88,000 5,705 502,040,000 0.05 (3 minutes) 25,102,000 Total 503,759,000 27,250,750 1 There are no capital costs or operating and maintenance costs associated with this collection of information. 2 Numbers may not sum due to rounding. We have decreased our estimated burden associated with disclosures to reflect a decrease in related submissions over the past 3 years. Dated: September 30, 2022. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2022-21840 Filed 10-6-22; 8:45 am]
Connectionstraces to 2
1 reference not yet in our index
- 21 CFR 208
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources